Depo-testadiol, Intrinsa(testosterone enanthate)
Androgel, Depo-testadiol, Ditate, Fortesta, Intrinsa, Livensa, Natesto, Testim, Vogelxo, Xyosted (testosterone enanthate) is a small molecule pharmaceutical. Testosterone enanthate was first approved as Depo-testadiol on 1982-01-01. It is used to treat breast neoplasms, delayed puberty, and hypogonadism in the USA. It has been approved in Europe to treat psychological sexual dysfunctions.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Androgel, Fortesta, Natesto, Testim, Vogelxo, Xyosted (generic drugs available since 1982-01-01, discontinued: Androderm, Axiron, Delatestryl, Striant, Testoderm)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Estradiol cypionate
+
Testosterone cypionate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
DEPO-TESTADIOL | Pharmacia & Upjohn | N-017968 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Testosterone
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
NATESTO | Acerus Pharmaceuticals Corporation | N-205488 RX | 2014-05-28 | 1 products, RLD, RS |
TESTIM | Auxilium Pharmaceuticals | N-021454 RX | 2002-10-31 | 1 products, RLD, RS |
ANDROGEL | BESINS HLTHCARE | N-022309 RX | 2011-04-29 | 1 products, RLD, RS |
FORTESTA | Endo | N-021463 RX | 2010-12-29 | 1 products, RLD, RS |
VOGELXO | Upsher-Smith Laboratories | N-204399 RX | 2014-06-04 | 2 products |
Show 9 discontinued
Testosterone cypionate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TESTOSTERONE CYPIONATE | Slayback Pharma | N-216318 PEND | 2022-06-02 | 1 products, RLD |
Testosterone enanthate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
XYOSTED (AUTOINJECTOR) | Antares Pharma | N-209863 RX | 2018-09-28 | 3 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
androderm | New Drug Application | 2020-05-18 |
androgel | New Drug Application | 2023-03-07 |
axiron | New Drug Application | 2013-11-12 |
fortesta | New Drug Application | 2022-01-19 |
natesto | New Drug Application | 2021-12-22 |
striant | New Drug Application | 2009-11-19 |
testim | New Drug Application | 2021-08-25 |
testopel | ANDA | 2018-08-24 |
vogelxo | New Drug Application | 2020-07-09 |
xyosted | New Drug Application | 2020-11-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
breast neoplasms | EFO_0003869 | D001943 | C50 |
delayed puberty | HP_0000823 | D011628 | E30.0 |
hypogonadism | HP_0000815 | D007006 | E23.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Testosterone Cypionate, Testosterone Cypionate, Slayback Pharma Llc | |||
11311554 | 2039-03-25 | DP | |
11642355 | 2039-03-25 | DP | |
Testosterone Enanthate, Xyosted (Autoinjector), Antares Pharma Inc | |||
10646495 | 2038-08-30 | DP | |
9950125 | 2036-09-04 | DP | U-2418 |
9744302 | 2035-11-19 | DP | |
11191908 | 2035-10-18 | DP | |
10238662 | 2035-02-19 | DP | U-2418 |
10912782 | 2035-02-19 | DP | U-2418 |
11160751 | 2034-10-07 | DP | U-2418 |
10881798 | 2034-02-11 | DP | |
10821072 | 2033-06-04 | DP | U-2418 |
10357609 | 2031-08-21 | DP | |
10905827 | 2031-08-21 | DP | |
11446440 | 2031-08-21 | DP | |
10279131 | 2031-07-31 | DP | |
11497753 | 2030-03-19 | DP | |
8021335 | 2026-10-04 | DP | |
8562564 | 2026-01-24 | DP | |
9180259 | 2026-01-24 | DP | |
9533102 | 2026-01-24 | DP | |
9629959 | 2026-01-24 | DP | |
10478560 | 2026-01-24 | DP | |
11446441 | 2026-01-24 | DP | |
Testosterone, Natesto, Acerus | |||
11090312 | 2034-03-17 | U-1616 | |
8574622 | 2024-02-04 | DP | |
8784869 | 2024-02-04 | DP | |
8784882 | 2024-02-04 | DP | U-1557 |
8877230 | 2024-02-04 | U-1616 | |
Testosterone, Vogelxo, Upsher Smith Labs | |||
8785426 | 2034-02-11 | DP | U-1531 |
9295675 | 2034-02-11 | DP | U-1531 |
9662340 | 2034-02-11 | DP | U-1531 |
Testosterone, Axiron, Eli Lilly And Co | |||
8435944 | 2027-09-27 | U-1390 | |
8419307 | 2027-02-26 | U-1386 | |
8807861 | 2027-02-26 | DP | U-1563 |
9289586 | 2027-02-26 | U-1390 | |
8993520 | 2026-06-02 | U-1390 | |
9180194 | 2026-06-02 | U-1390 | |
8784878 | 2023-07-13 | DP | U-1545 |
Testosterone, Androgel, Besins Hlthcare | |||
8466136 | 2026-10-12 | DP | |
8466137 | 2026-10-12 | U-1103 | |
8466138 | 2026-10-12 | U-1103 | |
8486925 | 2026-10-12 | DP | |
8729057 | 2026-10-12 | DP | |
8741881 | 2026-10-12 | U-1103 | |
8754070 | 2026-10-12 | DP | |
8759329 | 2026-10-12 | DP | |
Testosterone, Testim, Auxilium Pharms Llc | |||
7320968 | 2025-01-18 | U-843 | |
7608605 | 2023-04-21 | U-1009 | |
7608606 | 2023-04-21 | U-1009 | |
7608607 | 2023-04-21 | U-1009 | |
7608608 | 2023-04-21 | U-1009 | |
7608609 | 2023-04-21 | U-1009 | |
7608610 | 2023-04-21 | U-1009 | |
7935690 | 2023-04-21 | U-1009 | |
8063029 | 2023-04-21 | U-843 | |
8178518 | 2023-04-21 | DP |
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03B: Androgens
— G03BA: 3-oxoandrosten (4) derivatives
— G03BA03: Testosterone
— G03E: Androgens and female sex hormones in combination
— G03EA: Androgens and estrogens
— G03EA02: Testosterone and estrogen
— G04: Urologicals
— G04C: Drugs used in benign prostatic hypertrophy
— G04CB: Testosterone-5-alpha reductase inhibitors for benign prostatic hypertrophy
HCPCS
Code | Description |
---|---|
J3121 | Injection, testosterone enanthate, 1 mg |
Clinical
Clinical Trials
3 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Precocious puberty | D011629 | E22.8 | — | 2 | — | — | — | 2 | |
Polyostotic fibrous dysplasia | D005359 | Orphanet_562 | Q78.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | TESTOSTERONE ENANTHATE |
INN | testosterone |
Description | Testosterone enanthate is a heptanoate ester and a sterol ester. It has a role as an androgen. It is functionally related to a testosterone. |
Classification | Small molecule |
Drug class | steroids (androgens, anabolics); antiandrogens |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |
Identifiers
PDB | — |
CAS-ID | 315-37-7 |
RxCUI | — |
ChEMBL ID | CHEMBL1200335 |
ChEBI ID | 9464 |
PubChem CID | 9416 |
DrugBank | DB00624 |
UNII ID | 3XMK78S47O (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Androgel - AbbVie
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Testopel - Auxilium Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Striant - Juniper Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Testim - Auxilium Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 110,045 documents
View more details
Safety
Black-box Warning
Black-box warning for: Androgel, Axiron
, Fortesta, Testim, Vogelxo, Xyosted
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more